Illumina, Inc. vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Illumina, Inc. trades at $190.56 (market cap $29.12B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52. The key difference: Illumina, Inc. is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | SGOV | |
|---|---|---|
Market Cap | $29.12B | — |
Sector | Health | Fixed Income |
52-Week High | $205.10 | $100.74 |
52-Week Low | $91.00 | $100.28 |
Enterprise Value | $30.48B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.51 with minimal daily movement, reflecting its role as a stable cash alternative. The ETF maintains a bearish technical signal from moving averages while oscillators show neutral momentum. Recent institutional activity includes mixed positioning changes, with Bank of America increasing holdings while Deane Retirement Strategies significantly reduced exposure. The fund offers monthly distributions with a current yield around 3.8%, attracting defensive positioning amid market volatility.
SGOV provides principal protection and liquidity with minimal interest rate risk, making it suitable for conservative investors seeking yield above traditional savings. Key risks include Federal Reserve policy changes impacting short-term rates and inflation dynamics affecting real returns. The ETF's stability and monthly income stream offer defensive characteristics during economic uncertainty, though limited upside potential compared to equity investments.
Trailing returns across standard periods
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →